首頁 > 市場調查報告書 > 醫療設備

體外診斷感染疾病

市場調查報告書

商品編碼

2126355

性行為感染（STI）診斷市場：策略性洞察與預測（2026-2035）

STI Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計性行為感染(STI) 診斷市場將從 2026 年的 132.1 億美元成長到 2035 年的 287.4 億美元，複合年成長率為 9.0%。

性行為感染(STI) 診斷市場正經歷一場重大變革，其驅動力在於向預防性篩檢、分子診斷和分散式檢查的模式轉移。這一市場演變的特點是，人們日益認知到許多性行為感染在早期階段並無症狀，因此，預防性篩檢而非基於症狀的診斷對於防止持續感染和長期併發症至關重要。核酸擴增技術、快速診斷檢驗和數位健康平台的融合，使得性行為感染的檢測速度更快、敏感度更高，而且越來越方便。隨著公共衛生計畫加強降低高風險族群的性行為感染發生率，醫療保健系統正在擴大檢測建議範圍，並將診斷納入預防性醫療保健流程。監管持續影響市場發展，因為診斷準確性直接影響治療策略和監測品質。隨著對分子檢測、多重檢測、即時檢測 (PoC) 平台和自採集解決方案的大量投資，性行為感染診斷正逐漸成為公共衛生和預防醫學的基石。

市場促進因素

性行為感染）負擔日益加重是推動STI診斷市場發展的主要動力。隨著感染率的上升，及時識別疾病的需求也日益成長，使得STI診斷變得至關重要。隨著醫療系統認知到延遲診斷對感染控制的影響，篩檢需求不斷增加。未被發現的感染疾病會導致疾病進一步傳播，並增加與治療晚期疾病相關的醫療成本。公共衛生機構正在擴大檢測舉措，以促進早期診斷和治療。這些努力正在增強對STI診斷服務的長期需求，並推動STI診斷使用量的持續成長。分子檢測的日益普及透過提高診斷準確性進一步加速了市場成長。分子診斷具有檢測性行為感染病原體的高分析靈敏度。由於臨床醫生需要準確識別感染，即使是無症狀感染者，醫療機構也擴大採用基於核酸增幅檢查（NAAT）的檢測方法。傳統方法在某些臨床情況下可能降低診斷效能。實驗室正在實施先進的分子診斷工作流程，以提高檢測率和診斷確定性。這種轉變正在支撐對分子STI診斷的持續需求。加強公共衛生篩檢計畫正在推動檢測和基礎設施投資的增加。國家疾病控制策略依賴廣泛的檢測服務。由於可靠的診斷數據對監測和預防計畫至關重要，各國政府正在加大對篩檢工作的投入。檢測覆蓋率不足會降低干預措施的有效性，並延誤疫情的識別。醫療衛生系統正透過與當地診所和公共衛生機構合作，擴大篩檢能力。這種擴展推動了對擴充性診斷解決方案的需求。即時檢測的普及提高了檢測的可用性和可近性。快速檢測技術支援在各種醫療環境中進行即時臨床決策。隨著患者和醫療服務提供者尋求更短的診斷時間，需求也不斷成長。依賴檢查室的工作流程通常會導致治療啟動延遲和患者追蹤率降低。診斷設備製造商正在開發快速攜帶式檢測解決方案，以提高可及性和易用性。

市場限制因素

先進分子診斷平台的高成本限制了其在資源匱乏的醫療系統中的應用。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。圍繞性行為感染（STI）的社會污名降低了高危險群的檢測參與率，並延誤了診斷。與性傳染感染相關的污名阻礙了人們尋求檢測和治療。檢測基礎設施和人員配備水準的差異限制了某些地區獲得高品質診斷服務的機會。缺乏專業的檢測設施和熟練人員阻礙了分子診斷技術的廣泛應用。複雜且因地區而異的法規給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
性行為感染感染：疾病概述
性行為感染感染（STI）診斷技術的進步
主要市場趨勢
全球性行為感染感染（STI）負擔分析
疾病盛行率分析
已確診患者族群的分析
測試數量分析
篩檢和診斷的現狀
病人歷程分析
市場規模表現分析
市場預測分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

性傳染感染診斷領域的新興技術
產品創新趨勢
臨床試驗分析
管道分析
即時診斷創新
多重檢測技術的進展
數位健康領域的人工智慧整合與連接
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：性行為感染感染（STI）診斷市場：展望分析

分析：按技術平台
分析：檢體類型
分析：透過臨床應用
分析：透過測試方法
分析：即時檢測與臨床檢查室檢測的比較。
分析：按最終使用者環境

第9章性行為感染感染（STI）診斷市場：細分市場分析

依產品類型
- 裝置
- 試劑和耗材
- 軟體和診斷分析解決方案
透過技術
- 核酸增幅檢查（NAAT）
- 聚合酵素鏈鎖反應（PCR）
- 免疫測量
- 快速診斷檢測（RDT）
- 次世代定序（NGS）
- 使用培養方法的測試
- 其他分子診斷技術
依疾病類型
- 披衣菌感染
- 淋病
- 梅毒
- 人類乳突病毒（HPV）
- 人類免疫力缺乏病毒（HIV）
- 單純皰疹病毒（HSV）
- 滴蟲病
- 其他性行為感染感染
依檢體類型
- 血液檢體
- 尿液檢體
- 陰道拭子
- 子宮頸拭子
- 尿道拭子
- 口腔及直腸檢體
最終用戶
- 醫院
- 診斷檢查室
- 性健康診所
- 診所
- 區域測試中心
- 家庭檢測服務

第10章：性行為感染（STI）診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章性行為感染（STI）診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
中國
日本
印度
澳洲
韓國
巴西
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Becton, Dickinson and Company
Danaher Corporation（Cepheid）
bioMerieux SA
QIAGEN NV
Thermo Fisher Scientific Inc.
Siemens Healthineers AG
OraSure Technologies, Inc.
Seegene Inc.
Trinity Biotech plc
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Revvity, Inc.

第14章性行為感染（STI）診斷市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009066

The STI Diagnostics Market is anticipated to grow at a CAGR of 9.0% from USD 13.21 billion in 2026 to USD 28.74 billion in 2035.

The STI diagnostics market is undergoing significant transformation driven by the paradigm shift toward proactive screening, molecular diagnostics, and decentralized testing. The market's evolution is characterized by the growing recognition that many STIs remain asymptomatic during early stages, requiring proactive screening rather than symptom-driven diagnosis to prevent continued transmission and long-term complications. The convergence of nucleic acid amplification technologies, rapid diagnostic tests, and digital health platforms is enabling faster, more sensitive, and increasingly accessible STI detection. Healthcare systems are expanding testing recommendations and integrating diagnostics into preventive care pathways as public health programs strengthen efforts to reduce STI incidence among high-risk populations. Regulatory oversight continues shaping market development because diagnostic accuracy directly influences treatment decisions and surveillance quality. The market is witnessing significant investment in molecular testing, multiplex panels, point-of-care platforms, and self-collection solutions, positioning STI diagnostics as a cornerstone of public health and preventive medicine.

Market Drivers

The increasing burden of sexually transmitted infections represents the primary driver for the STI diagnostics market. STI diagnostics remain essential because rising infection rates increase the need for timely disease identification. Screening demand is increasing as healthcare systems recognize the consequences of delayed diagnosis on transmission control. Undetected infections contribute to broader disease spread and increase healthcare costs associated with advanced disease management. Public health agencies are expanding testing initiatives that encourage earlier diagnosis and treatment. This effort strengthens long-term demand for STI diagnostic services, resulting in sustained growth in STI diagnostic utilization. The expansion of molecular testing adoption is further accelerating market growth through improved diagnostic accuracy. Molecular diagnostics provide high analytical sensitivity for detecting sexually transmitted pathogens. Healthcare providers are increasingly adopting NAAT-based testing because clinicians require accurate identification of infections even when symptoms are absent. Conventional methods may produce lower diagnostic performance in certain clinical settings. Laboratories are implementing advanced molecular workflows that improve detection rates and diagnostic confidence. This transition supports sustained demand for molecular STI diagnostics. Strengthening public health screening programs is increasing testing volumes and infrastructure investment. National disease control strategies depend on widespread access to testing services. Governments are increasing investments in screening initiatives because surveillance and prevention programs require reliable diagnostic data. Limited testing coverage reduces the effectiveness of intervention efforts and delays outbreak recognition. Healthcare systems are expanding screening capacity through community clinics and public health partnerships. This expansion increases demand for scalable diagnostic solutions. The growth of point-of-care testing is expanding utilization and improving accessibility. Rapid testing technologies support immediate clinical decision-making in diverse healthcare environments. Demand is increasing because patients and providers seek shorter diagnostic timelines. Laboratory-dependent workflows often delay treatment initiation and reduce patient follow-up rates. Diagnostic companies are developing rapid and portable testing solutions that improve accessibility and convenience.

Market Restraints

High costs associated with advanced molecular diagnostic platforms limit adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Social stigma surrounding sexually transmitted infections reduces testing participation and delays diagnosis among at-risk populations. The stigma associated with STIs creates barriers to testing and treatment seeking. Uneven laboratory infrastructure and workforce availability restrict access to high-quality diagnostic services in certain regions. The shortage of specialized laboratories and skilled personnel limits the scalability of molecular diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of molecular diagnostics and decentralized testing solutions. NAAT technologies represent a major component of STI diagnostics because they provide high analytical sensitivity for pathogen detection. Demand is increasing as healthcare providers seek earlier identification of infections among asymptomatic individuals. PCR remains a foundational technology for molecular detection, providing high sensitivity and specificity. Immunoassays continue supporting serological testing for syphilis, HIV, and other infections. Rapid diagnostic tests are expanding for point-of-care and self-testing applications. NGS is emerging for surveillance and resistance monitoring. The segment analysis reveals that chlamydia testing generates substantial demand because the infection frequently remains asymptomatic while contributing to significant reproductive health complications. Screening programs are expanding as healthcare systems prioritize early intervention. Gonorrhea, syphilis, HPV, HIV, and HSV represent significant testing segments with expanding screening recommendations. Urine samples, vaginal swabs, and blood samples constitute primary specimen types. Diagnostic laboratories represent the leading end-user segment, with hospitals, sexual health clinics, and community testing centers expanding screening capacity. The growth of home testing services is expanding accessibility and convenience. The integration of digital health platforms is becoming increasingly important because STI testing increasingly relies on efficient communication of results and follow-up recommendations. Technology providers are integrating diagnostics with digital reporting and telehealth services that improve care coordination.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized molecular, rapid test, and digital health providers. Abbott is strategically distinct because it combines global diagnostics scale, extensive infectious disease expertise, and strong penetration across laboratory and point-of-care testing environments, strengthening molecular and infectious disease testing capabilities that support rapid and reliable pathogen detection. Roche differentiates itself through its leadership in molecular diagnostics and extensive experience in infectious disease testing, expanding molecular testing capabilities that improve diagnostic confidence while supporting high-volume laboratory operations. Hologic occupies a strategically important position because of its strong focus on women's health diagnostics and molecular testing technologies, expanding molecular testing capabilities through automated platforms that support accurate and efficient screening. BD remains an important participant because of its expertise in microbiology, specimen management, and laboratory automation, strengthening automation capabilities and laboratory integration solutions that improve testing efficiency. Danaher, through Cepheid, is strategically distinct because it combines rapid molecular diagnostics with near-patient testing capabilities, expanding cartridge-based molecular testing solutions that simplify implementation while delivering highly sensitive results. bioMerieux differentiates itself through its expertise in infectious disease diagnostics, microbiology, and laboratory informatics, strengthening diagnostic connectivity and workflow integration capabilities. QIAGEN combines sample preparation technologies, molecular diagnostics, and bioinformatics capabilities within a unified diagnostic ecosystem, expanding molecular diagnostic workflows that improve pathogen detection. Companies are pursuing product portfolio expansion through innovation in molecular assays, multiplex panels, and point-of-care platforms. Strategic collaborations between diagnostic manufacturers and public health organizations are increasing, driven by the need for screening and surveillance. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The STI diagnostics market is positioned for sustained growth driven by the convergence of rising STI burden, molecular testing adoption, and public health screening initiatives. The transition from symptom-driven testing toward proactive screening and decentralized diagnostics represents a fundamental evolution in STI management. While challenges related to high costs, stigma, and infrastructure limitations persist, strategic investments in technology, accessibility, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with STI diagnostics evolving into a cornerstone of public health and preventive medicine, supporting early detection, treatment, and disease surveillance across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. STI Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Sexually Transmitted Infections: Disease Overview
3.3 Evolution of STI Diagnostic Technologies
3.4 Key Market Trends
3.5 Global STI Burden Analysis
3.6 Disease Prevalence Analysis
3.7 Diagnosed Patient Population Analysis
3.8 Testing Volume Analysis
3.9 Screening and Diagnostic Landscape
3.10 Patient Journey Analysis
3.11 Historical Market Size Analysis (2021-2025)
3.12 Market Forecast Analysis (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies in STI Diagnostics
6.2 Product Innovation Trends
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Point-of-Care Diagnostic Innovation
6.6 Multiplex Testing Developments
6.7 AI Integration and Digital Health Connectivity
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. STI Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Sample Type
8.3 Analysis by Clinical Application
8.4 Analysis by Testing Methodology
8.5 Analysis by Point-of-Care vs Laboratory-Based Testing
8.6 Analysis by End-user Environment

9. STI Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software & Diagnostic Analytics Solutions
9.2 By Technology
- 9.2.1 Nucleic Acid Amplification Tests (NAATs)
- 9.2.2 Polymerase Chain Reaction (PCR)
- 9.2.3 Immunoassays
- 9.2.4 Rapid Diagnostic Tests (RDTs)
- 9.2.5 Next-Generation Sequencing (NGS)
- 9.2.6 Culture-Based Testing
- 9.2.7 Other Molecular Diagnostic Technologies
9.3 By Disease Type
- 9.3.1 Chlamydia
- 9.3.2 Gonorrhea
- 9.3.3 Syphilis
- 9.3.4 Human Papillomavirus (HPV)
- 9.3.5 Human Immunodeficiency Virus (HIV)
- 9.3.6 Herpes Simplex Virus (HSV)
- 9.3.7 Trichomoniasis
- 9.3.8 Other Sexually Transmitted Infections
9.4 By Sample Type
- 9.4.1 Blood Samples
- 9.4.2 Urine Samples
- 9.4.3 Vaginal Swabs
- 9.4.4 Cervical Swabs
- 9.4.5 Urethral Swabs
- 9.4.6 Oral and Rectal Samples
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Diagnostic Laboratories
- 9.5.3 Sexual Health Clinics
- 9.5.4 Physician Offices
- 9.5.5 Community Testing Centers
- 9.5.6 Home Testing Services